Compare Figs Inc (FIGS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Natera Inc. Common Stock — how do they compare? Figs Inc trades at $18.54 (market cap $2.99B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 19.1× Figs Inc's market cap, and Figs Inc is trading nearer its 52-week high, Natera Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 31 Days and Natera Inc. Common Stock for 0 Days on average.
| FIGS | NTRA | |
|---|---|---|
Market Cap | $2.99B | $57.03B |
Volume | 6,721,481 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.63 | $425.64 |
52-Week Low | $7.38 | $179.42 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.75B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $18.63, up 4.9% today, showing strong momentum with three consecutive quarterly earnings beats. The company demonstrates robust fundamentals with 68.9% gross margins and accelerating revenue growth from $556M in 2024 to projected $710M in 2026. Technical indicators show bullish momentum with the stock trading near resistance at $19, though RSI levels suggest potential overbought conditions. Recent news highlights international expansion success with 67% Q2 international sales growth and raised 2026 guidance.
The outlook remains positive with analyst consensus pointing to 26% upside potential to $18 target, though the premium valuation (P/E 54.6) requires continued execution. Key risks include rich valuation multiples and competitive pressures in healthcare apparel. The combination of strong earnings momentum, international growth, and bullish technicals supports further upside if the company maintains its growth trajectory.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
